Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer

Malik E. Juweid, Mark Tulchinsky, Ayman Mismar, Munther Momani, Ayman A. Zayed, Hussam Al Hawari, Nader Albsoul, Felix M. Mottaghy

Research output: Contribution to journalReview articlepeer-review

Abstract

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy with a growing incidence worldwide. The initial conventional management is surgery, followed by consideration of 131I treatment that includes three options. These are termed remnant ablation (targeting benign thyroid remnant), adjuvant (targeting presumed microscopic DTC) and known disease (targeting macroscopic DTC) treatments. Some experts mostly rely on clinicopathologic assessment for recurrence risk to select patients for the 131I treatment. Others, in addition, apply radioiodine imaging to guide their treatment planning, termed theranostics (aka theragnostics or radiotheragnostics). In patients with low-risk DTC, remnant ablation rather than adjuvant treatment is generally recommended and, in this setting, the ATA recommends a low 131I activity. 131I adjuvant treatment is universally recommended in patients with high-risk DTC (a primary tumor of any size with gross extrathyroidal extension) and is generally recommended in intermediate-risk DTC (primary tumor >4 cm in diameter, locoregional metastases, microscopic extrathyroidal extension, aggressive histology or vascular invasion). The optimal amount of 131I activity for adjuvant treatment is controversial, but experts reached a consensus that the 131I activity should be greater than that for remnant ablation. The main obstacles to establishing timely evidence through randomized clinical trials for 131I therapy include years-to-decades delay in recurrence and low disease-specific mortality. This mini-review is intended to update oncologists on the most recent clinical, pathologic, laboratory and imaging variables, as well as on the current 131I therapy-related definitions and management paradigms, which should optimally equip them for individualized patient guidance and treatment.

Original languageEnglish (US)
Pages (from-to)2345-2354
Number of pages10
JournalInternational Journal of Cancer
Volume147
Issue number9
DOIs
StatePublished - Nov 1 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer'. Together they form a unique fingerprint.

Cite this